Shu Chen, Qin Li, Huaqiang Liao, Mingcai Zhao, Jie Chen, Hongyu Chen, Guangjun Xiao
{"title":"Establishment and application of a preset dilution factor strategy for human chorionic gonadotropin testing in clinical laboratory.","authors":"Shu Chen, Qin Li, Huaqiang Liao, Mingcai Zhao, Jie Chen, Hongyu Chen, Guangjun Xiao","doi":"10.3389/fmolb.2025.1648421","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Automated dilution has improved the efficiency of human chorionic gonadotropin (hCG) testing, however, challenges persist regarding the cost implications of repeated testing. This study proposes the concept of cost-effective optimization, which aims to further optimize testing efficiency while maintaining controllable costs, and establishes an automated process with preset dilution factors for the hCG testing.</p><p><strong>Materials and methods: </strong>The hCG testing process at Suining Central Hospital was optimized using the Aptio™ Automation Solution (Siemens Healthineers, Erlangen, Germany) integrated with Siemens Atellica® IM1600 analyzer. A novel middleware program was developed within the DataLink V2.0 (Siemens Healthineers, Erlangen, Germany) to automate dilution factor assignment. Relevant data such as dilution factors, sample reception time and review time were captured for statistical purposes to analyze the accuracy, ability to shorten TAT, and economic benefits of hCG testing.</p><p><strong>Results: </strong>After 8 months of continuous improvement, implementation of automated hCG dilution attained 91.19% compliance rate with 19.7% reduction in in-laboratory TAT. The process achieved 75.60% compliance against the 90 min benchmark, while the preset dilution process generated 15.03% mean cost savings per test.</p><p><strong>Conclusion: </strong>In this study, a preset dilution factor program was utilized to establish an automated dilution process, achieving accurate and rapid prediction of hCG. These strategies not only improve efficiency, but also effectively reduce costs, enabling the expansion of testing items and facilitating the implementation in laboratories. Furthermore, they also help to shorten the in-hospital TAT for patients, and improve the hospital's service quality.</p>","PeriodicalId":12465,"journal":{"name":"Frontiers in Molecular Biosciences","volume":"12 ","pages":"1648421"},"PeriodicalIF":3.9000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12440790/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Molecular Biosciences","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3389/fmolb.2025.1648421","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Automated dilution has improved the efficiency of human chorionic gonadotropin (hCG) testing, however, challenges persist regarding the cost implications of repeated testing. This study proposes the concept of cost-effective optimization, which aims to further optimize testing efficiency while maintaining controllable costs, and establishes an automated process with preset dilution factors for the hCG testing.
Materials and methods: The hCG testing process at Suining Central Hospital was optimized using the Aptio™ Automation Solution (Siemens Healthineers, Erlangen, Germany) integrated with Siemens Atellica® IM1600 analyzer. A novel middleware program was developed within the DataLink V2.0 (Siemens Healthineers, Erlangen, Germany) to automate dilution factor assignment. Relevant data such as dilution factors, sample reception time and review time were captured for statistical purposes to analyze the accuracy, ability to shorten TAT, and economic benefits of hCG testing.
Results: After 8 months of continuous improvement, implementation of automated hCG dilution attained 91.19% compliance rate with 19.7% reduction in in-laboratory TAT. The process achieved 75.60% compliance against the 90 min benchmark, while the preset dilution process generated 15.03% mean cost savings per test.
Conclusion: In this study, a preset dilution factor program was utilized to establish an automated dilution process, achieving accurate and rapid prediction of hCG. These strategies not only improve efficiency, but also effectively reduce costs, enabling the expansion of testing items and facilitating the implementation in laboratories. Furthermore, they also help to shorten the in-hospital TAT for patients, and improve the hospital's service quality.
期刊介绍:
Much of contemporary investigation in the life sciences is devoted to the molecular-scale understanding of the relationships between genes and the environment — in particular, dynamic alterations in the levels, modifications, and interactions of cellular effectors, including proteins. Frontiers in Molecular Biosciences offers an international publication platform for basic as well as applied research; we encourage contributions spanning both established and emerging areas of biology. To this end, the journal draws from empirical disciplines such as structural biology, enzymology, biochemistry, and biophysics, capitalizing as well on the technological advancements that have enabled metabolomics and proteomics measurements in massively parallel throughput, and the development of robust and innovative computational biology strategies. We also recognize influences from medicine and technology, welcoming studies in molecular genetics, molecular diagnostics and therapeutics, and nanotechnology.
Our ultimate objective is the comprehensive illustration of the molecular mechanisms regulating proteins, nucleic acids, carbohydrates, lipids, and small metabolites in organisms across all branches of life.
In addition to interesting new findings, techniques, and applications, Frontiers in Molecular Biosciences will consider new testable hypotheses to inspire different perspectives and stimulate scientific dialogue. The integration of in silico, in vitro, and in vivo approaches will benefit endeavors across all domains of the life sciences.